Virtus Investment Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Virtus Investment Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.3M	Sell	2,614 -3,255	-55%	-$1.44M	0.3%	153
2026 Q1	$2.62M	Buy	5,869 +4,358	+288%	+$2.03M	0.72%	5
2025 Q4	$685K	Buy	1,511 +545	+56%	+$235K	0.19%	178
2025 Q3	$378K	Hold	966	–	–	0.11%	233
2025 Q2	$430K	Buy	966 +193	+25%	+$88.9K	0.15%	212
2025 Q1	$375K	Buy	+773	New	+$360K	0.1%	219
2023 Q1	–	Sell	-1,317	Closed	-$380K	–	343
2022 Q4	$380K	Hold	1,317	–	–	0.25%	123
2022 Q3	$381K	Buy	+1,317	New	+$379K	0.18%	121
2018 Q1	–	Sell	-1,069	Closed	-$160K	–	425
2017 Q4	$160K	Sell	1,069 -17	-2%	-$2.52K	0.02%	422
2017 Q3	$165K	Sell	1,086 -134	-11%	-$20.2K	0.02%	432
2017 Q2	$157K	Sell	1,220 -104	-8%	-$12.5K	0.02%	448
2017 Q1	$145K	Buy	+1,324	New	+$117K	0.01%	429
2016 Q4	–	Sell	-5,279	Closed	-$460K	–	527
2016 Q3	$460K	Buy	+5,279	New	+$499K	0.03%	366

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Virtus Investment Advisers's VRTX Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Vertex Pharmaceuticals (VRTX) stake by 55% in Q2 2026, selling an estimated $1.44M and leaving 2,614 shares worth $1.3M. The position accounts for 0.3% of the portfolio, ranked #153.

Virtus Investment Advisers first reported a position in VRTX in Q3 2016 and has held it in 13 quarters since. The position peaked at $2.62M in Q1 2026. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Virtus Investment Advisers held 2,614 shares of Vertex Pharmaceuticals worth $1.3M as of Q2 2026.
Virtus Investment Advisers sold 3,255 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
Vertex Pharmaceuticals made up 0.3% of Virtus Investment Advisers's portfolio in Q2 2026, its #153 holding.
Virtus Investment Advisers first reported a position in Vertex Pharmaceuticals in Q3 2016 and has held it in 13 quarters since.
Virtus Investment Advisers's Vertex Pharmaceuticals position peaked at $2.62M in Q1 2026.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.